1. Home
  2. ADTX

as of 02-17-2026 2:20pm EST

$0.61
$0.01
-1.17%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.

Founded: 2017 Country:
N/A
Employees: N/A City: RICHMOND
Market Cap: 1.1M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 3.4M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.58 - $4463.48 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 15768.94% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered ADTX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 79.11%
79.11%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Aditxt Inc. (ADTX)

Pankovcin Corinne

Chief M&A Officer

Sell
ADTX Nov 25, 2025

Avg Cost/Share

$3.20

Shares

1

Total Value

$3.20

Owned After

0

SEC Form 4

Compare ADTX vs Leading Stocks

See how ADTX stacks up against similar companies in the market

Quick Access: Similar Stocks

Share on Social Networks: